---
title: "CHINARES PHARMA's asthma inhalation powder has been approved by the FDA for market launch"
description: "CHINARES PHARMA announced that its subsidiary Runsheng Pharmaceutical's salmeterol/fluticasone inhalation powder has received marketing approval from the U.S. Food and Drug Administration (FDA), marki"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/272792273.md"
published_at: "2026-01-16T06:13:29.000Z"
---

# CHINARES PHARMA's asthma inhalation powder has been approved by the FDA for market launch

> CHINARES PHARMA announced that its subsidiary Runsheng Pharmaceutical's salmeterol/fluticasone inhalation powder has received marketing approval from the U.S. Food and Drug Administration (FDA), marking the first time the FDA has approved an inhalation powder developed independently by a Chinese pharmaceutical company. The salmeterol/fluticasone inhalation powder is used in a combination therapy (bronchodilator and inhaled corticosteroid) for the regular treatment of reversible obstructive airway diseases, including asthma in adults and children

China Resources Pharmaceutical (03320.HK) announced that its subsidiary Runsheng Pharmaceutical has received approval from the U.S. Food and Drug Administration (FDA) for the market launch of salmeterol/fluticasone inhalation powder, marking the first time the FDA has approved an inhalation powder developed independently by a Chinese pharmaceutical company.

The salmeterol/fluticasone inhalation powder is used in a combination therapy (bronchodilator and inhaled corticosteroid) for the regular treatment of reversible obstructive airway diseases, including asthma in adults and children

### Related Stocks

- [03320.HK - CHINARES PHARMA](https://longbridge.com/en/quote/03320.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 10:31 ETRespiratory Care Devices Market to Reach $47.9 billion, Globally, by 2033 at 7.6% CAGR: Allied Market Research | The global respiratory care devices market is projected to grow from $22.9 billion in 2023 to $47.9 billion by 2033, at  | [Link](https://longbridge.com/en/news/275778433.md) |
| Anta Sports Products gets written shareholders' approvals from Anta International, units | Anta Sports Products gets written shareholders' approvals from Anta International, units | [Link](https://longbridge.com/en/news/275885036.md) |
| Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | [Link](https://longbridge.com/en/news/275851575.md) |
| A sexually transmitted ringworm is spreading in one US state | Minnesota is experiencing the largest outbreak of sexually transmitted ringworm (TMVII) in the U.S., with over 30 confir | [Link](https://longbridge.com/en/news/275977276.md) |
| BUZZ-Upstream Bio jumps as experimental asthma drug shows promise in mid‑stage study | Shares of Upstream Biosurged 20% to $32.64 in premarket trading following positive results from a mid-stage study of its | [Link](https://longbridge.com/en/news/275596211.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.